Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Malformations | 3 | 2020 | 101 | 1.350 |
Why?
|
| Pierre Robin Syndrome | 1 | 2021 | 5 | 0.800 |
Why?
|
| Osteogenesis, Distraction | 1 | 2021 | 72 | 0.770 |
Why?
|
| Lymphatic Abnormalities | 1 | 2019 | 22 | 0.700 |
Why?
|
| Vascular Neoplasms | 1 | 2018 | 20 | 0.660 |
Why?
|
| Laser Therapy | 1 | 2018 | 91 | 0.620 |
Why?
|
| Hemangioma | 1 | 2018 | 83 | 0.610 |
Why?
|
| Vascular Surgical Procedures | 1 | 2019 | 178 | 0.610 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2018 | 177 | 0.580 |
Why?
|
| Estrogens | 3 | 2008 | 244 | 0.540 |
Why?
|
| Aging | 3 | 2008 | 784 | 0.410 |
Why?
|
| Interleukin-1 | 2 | 2006 | 107 | 0.340 |
Why?
|
| Lipopolysaccharides | 3 | 2008 | 199 | 0.340 |
Why?
|
| Cleft Palate | 2 | 2021 | 72 | 0.310 |
Why?
|
| Treatment Outcome | 5 | 2021 | 5604 | 0.290 |
Why?
|
| Blood Cells | 1 | 2005 | 58 | 0.250 |
Why?
|
| Microglia | 1 | 2005 | 137 | 0.230 |
Why?
|
| Gills | 1 | 2021 | 8 | 0.200 |
Why?
|
| Lip | 1 | 2021 | 11 | 0.200 |
Why?
|
| Velopharyngeal Insufficiency | 1 | 2021 | 21 | 0.200 |
Why?
|
| Eustachian Tube | 1 | 2021 | 15 | 0.190 |
Why?
|
| Air Microbiology | 1 | 2020 | 12 | 0.190 |
Why?
|
| Craniofacial Abnormalities | 1 | 2021 | 27 | 0.190 |
Why?
|
| Adenoidectomy | 1 | 2020 | 34 | 0.190 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2020 | 38 | 0.190 |
Why?
|
| Tonsillectomy | 1 | 2020 | 49 | 0.190 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2020 | 52 | 0.190 |
Why?
|
| Lasers, Solid-State | 1 | 2020 | 32 | 0.180 |
Why?
|
| Veins | 1 | 2020 | 74 | 0.180 |
Why?
|
| Patient Safety | 1 | 2021 | 121 | 0.180 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 84 | 0.180 |
Why?
|
| Surgical Wound Infection | 1 | 2020 | 126 | 0.180 |
Why?
|
| Cryosurgery | 1 | 2018 | 38 | 0.160 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2018 | 80 | 0.160 |
Why?
|
| Patient Selection | 1 | 2019 | 286 | 0.160 |
Why?
|
| Brain | 1 | 2006 | 1387 | 0.150 |
Why?
|
| Ovariectomy | 3 | 2008 | 125 | 0.150 |
Why?
|
| Gastroesophageal Reflux | 1 | 2017 | 49 | 0.150 |
Why?
|
| Eosinophilic Esophagitis | 1 | 2017 | 32 | 0.150 |
Why?
|
| Algorithms | 1 | 2021 | 697 | 0.150 |
Why?
|
| Drug Interactions | 3 | 2008 | 206 | 0.150 |
Why?
|
| Skin | 1 | 2020 | 469 | 0.150 |
Why?
|
| Deglutition Disorders | 1 | 2017 | 71 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 432 | 0.140 |
Why?
|
| Retrospective Studies | 4 | 2021 | 6432 | 0.140 |
Why?
|
| Tongue Diseases | 1 | 2015 | 5 | 0.140 |
Why?
|
| Salivary Glands | 1 | 2015 | 10 | 0.130 |
Why?
|
| Choristoma | 1 | 2015 | 22 | 0.130 |
Why?
|
| Tongue | 1 | 2015 | 41 | 0.130 |
Why?
|
| Humans | 9 | 2021 | 54284 | 0.130 |
Why?
|
| Risk Factors | 2 | 2020 | 3935 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2018 | 1361 | 0.120 |
Why?
|
| Animals | 4 | 2021 | 14385 | 0.120 |
Why?
|
| Infant, Newborn | 2 | 2018 | 2907 | 0.110 |
Why?
|
| Female | 8 | 2020 | 28441 | 0.110 |
Why?
|
| Prognosis | 1 | 2018 | 2118 | 0.110 |
Why?
|
| Gene Expression Regulation | 2 | 2008 | 1062 | 0.100 |
Why?
|
| Rats | 3 | 2008 | 3415 | 0.090 |
Why?
|
| Olfactory Bulb | 2 | 2008 | 14 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2008 | 434 | 0.070 |
Why?
|
| Astrocytes | 1 | 2008 | 142 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2020 | 4147 | 0.070 |
Why?
|
| Male | 4 | 2020 | 27334 | 0.070 |
Why?
|
| Corticosterone | 1 | 2006 | 17 | 0.070 |
Why?
|
| Time | 1 | 2006 | 36 | 0.070 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2006 | 41 | 0.070 |
Why?
|
| Colorimetry | 1 | 2005 | 12 | 0.070 |
Why?
|
| Nitrites | 1 | 2005 | 39 | 0.070 |
Why?
|
| Nitrates | 1 | 2005 | 49 | 0.060 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2005 | 93 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2008 | 1737 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2006 | 635 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 673 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 314 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2020 | 2604 | 0.060 |
Why?
|
| Child | 3 | 2021 | 7341 | 0.060 |
Why?
|
| Inflammation | 1 | 2008 | 674 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2005 | 683 | 0.060 |
Why?
|
| Gene Expression | 1 | 2006 | 664 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2005 | 298 | 0.050 |
Why?
|
| Cytokines | 1 | 2006 | 676 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2006 | 1202 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2006 | 1663 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 1089 | 0.050 |
Why?
|
| Infant | 2 | 2020 | 3817 | 0.050 |
Why?
|
| Pharynx | 1 | 2021 | 39 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 1476 | 0.050 |
Why?
|
| Nasopharynx | 1 | 2020 | 32 | 0.050 |
Why?
|
| Photography | 1 | 2020 | 39 | 0.050 |
Why?
|
| Developing Countries | 1 | 2021 | 53 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2020 | 120 | 0.050 |
Why?
|
| Risk | 1 | 2020 | 343 | 0.040 |
Why?
|
| Liver | 1 | 2006 | 1225 | 0.040 |
Why?
|
| Poverty | 1 | 2021 | 231 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2020 | 742 | 0.040 |
Why?
|
| Adolescent | 2 | 2020 | 6897 | 0.040 |
Why?
|
| Constipation | 1 | 2017 | 33 | 0.040 |
Why?
|
| Vomiting | 1 | 2017 | 73 | 0.040 |
Why?
|
| Diarrhea | 1 | 2017 | 90 | 0.040 |
Why?
|
| Esophagus | 1 | 2017 | 79 | 0.040 |
Why?
|
| Food Hypersensitivity | 1 | 2017 | 96 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2020 | 1543 | 0.030 |
Why?
|
| Laryngoscopy | 1 | 2015 | 62 | 0.030 |
Why?
|
| Abnormalities, Multiple | 1 | 2015 | 159 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 1136 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 4318 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2008 | 37 | 0.020 |
Why?
|
| N-Methylaspartate | 1 | 2008 | 27 | 0.020 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2008 | 23 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2008 | 47 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 61 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2008 | 78 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2008 | 131 | 0.020 |
Why?
|
| Adult | 1 | 2020 | 14207 | 0.020 |
Why?
|